uploads///Chart  Consumer

Johnson & Johnson’s Consumer Segment: 4Q17 Estimates

By

Jan. 22 2018, Updated 7:34 a.m. ET

Consumer segment

Johnson & Johnson’s (JNJ) Consumer segment includes oral care products, beauty products, baby care products, over-the-counter products, women’s health products, and wound care products. The segment is expected to have positive growth in revenues for 4Q17.

The above chart compares revenues for the Consumer segment over the last eight quarters.

Article continues below advertisement

Oral care franchise

The oral care franchise is expected to report a decline in revenues in 4Q17 due to weaker sales in the US markets. A strong expected performance of Total Care Zero and whitening products is expected to offset the decline in revenues.

Beauty franchise

Johnson & Johnson’s beauty franchise is expected to report growth in revenues in 4Q17 due to the strong performance of products acquired from Vogue International and some new products. It’s expected to be partially offset by lower sales from EMEA (Europe, the Middle East, and Africa) markets.

Article continues below advertisement

Over-the-counter franchise

The over-the-counter franchise is expected to report growth in revenues in 4Q17 due to strong sales of analgesics and Tylenol and the inclusion of Rhinocort, partially offset by lower sales of Zyrtec.

Wound care franchise

The wound care franchise is expected to report growth in revenues in 4Q17 due to new product launches in international markets, partially offset by lower sales in US markets.

Article continues below advertisement

Baby care franchise

The baby care franchise is expected to report a decline in revenues in 4Q17 following lower sales due to competition.

Women’s health franchise

The women’s health franchise is expected to report growth in revenues in 4Q17 following new product launches, partially offset by lower sales in US markets.

The VanEck Vectors Pharmaceutical ETF (PPH) holds 4.6% of its total investments in Johnson & Johnson (JNJ), 4.7% in Pfizer (PFE), 4.9% in GlaxoSmithKline (GSK), and 4.8% in AstraZeneca (AZN).

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market RealistLogo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.